Chinese Journal of Cancer Research

Papers
(The TQCC of Chinese Journal of Cancer Research is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Gastric cancer surgery in South Korea: Past, present, and future84
Efficacy of ctDNA methylation combined with traditional detection modality to detect liver cancer among high-risk patients: A multicenter diagnostic trial75
Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial59
Pathogenic germline variants in mismatch repair genes in patients with microsatellite instability-high gastric cancer52
Focal ablation therapy presents promising results for selectively localized prostate cancer patients39
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas39
Heterogeneity of tumor-infiltrating myeloid cells in era of single-cell genomics37
Transforming cancer cells for long-term living with cancer: An inspiring new approach37
Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis35
Gut microbiota and acute graft-versus-host disease34
Plasma cell-free DNA methylation markers for detection and prognosis of gastric cancer: A case-control study33
National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)30
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives29
Detection and classification of breast lesions using multiple information on contrast-enhanced mammography by a multiprocess deep-learning system: A multicenter study28
Mn-based cGAS-STING activation for tumor therapy27
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors27
Updates of CSCO guidelines for colorectal cancer version 202527
Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer22
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China22
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery: Final results of a phase II trial20
Impact of resection margin status on survival in gastric cancer: A retrospective cohort study19
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A18
Comparison of short- and long-term outcomes of robotic vs. laparoscopic gastrectomy for clinical serosa-invasive gastric cancer: A multicenter cohort study17
New roles of tumor-derived exosomes in tumor microenvironment17
Optimal response population after neoadjuvant therapy for patients with locally advanced gastric cancer: A multicenter study17
Health economic evaluation on population-based Helicobacter pylori eradication and endoscopic screening for gastric cancer prevention16
Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study15
Hypoxic tumor microenvironment: Destroyer of natural killer cell function15
Burden of liver cancer: From epidemiology to prevention15
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma14
Corrigendum to Comments on National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)14
Pan-cancer tumor-infiltrating T cells: A great hallmark in cancer immunology research14
Postoperative chemoradiotherapy with capecitabine and oxaliplatin vs. capecitabine for pathological stage N2 rectal cancer14
Genomic characterization of peritoneal lavage cytology-positive gastric cancer13
Long-term adherence to gastric cancer screening in South Korea: A 10-year follow-up study12
Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: A nationwide multicenter cross-sectional study12
Lung cancer burden and trends from 2000 to 2018 in China: Comparison between China and the United State12
Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors12
Research progress of minimally invasive surgery for gastric cancer11
Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors11
Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer10
Comments on National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version)10
Adjuvant therapy for hormone receptor-positive breast cancer: Perspective from a survey on breast cancer physicians’ acceptance of practice-changing data10
Update of latest data for combined therapy for esophageal cancer using radiotherapy and immunotherapy: A focus on efficacy, safety, and biomarkers9
Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies9
Development and validation of machine learning-based survival analysis to predict outcome in gastric cancer with adjuvant chemotherapy: A multicenter, longitudinal, cohort study9
Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer9
Postoperative functional evaluation of gastrectomy for gastric cancer9
SOX11 as a potential prognostic biomarker in hepatocellular carcinoma linked to immune infiltration and ferroptosis9
High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China9
Variant rs8400 enhances ALKBH5 expression through disrupting miR-186 binding and promotes neuroblastoma progression9
Advances, breakthroughs, and challenges in gastric cancer surgery9
Clinicopathological and molecular features of HR+/HER2− breast cancer patients with distinct endocrine resistance patterns8
Allogeneic hematopoietic cell transplantation in vulnerable populations: Advances and perspectives8
Discovery and validation of indole nitroolefins as novel covalent GPX4 inhibitors for inducing ferroptosis in urological cancers8
Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in 8
Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment7
Effectiveness and safety of combined nimotuzumab and S-1 chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer in malnourished and elderly patients: A prospective phase II s7
Inducing immunogenic cell death in immuno-oncological therapies7
Manufacturing CAR-NK against tumors: Who is the ideal supplier?7
Neoadjuvant chemotherapy with capecitabine combined with oxaliplatin for mid-low locally advanced rectal cancer with negative mesorectal fascia: Long-term outcomes of a prospective trial (PKUCH-R03 tr7
Laparoscopic vs. open lower mediastinal lymphadenectomy for Siewert type II/III adenocarcinoma of esophagogastric junction: An exploratory, observational, prospective, IDEAL stage 2b cohort study (CLA7
Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis7
Myeloid cells meet CD8+ T cell exhaustion in cancer: What, why and how7
Distal margin distance in radical resection of locally advanced rectal cancer after neoadjuvant therapy7
Homoharringtonine combined with venetoclax and azacitidine: An effective and safe regimen for patients with refractory/relapsed acute myeloid leukemia7
0.077354907989502